论文部分内容阅读
目的:比较单纯化学药物化疗治疗方案与化疗联合贝伐单抗或西妥昔单抗治疗对于治疗晚期结直肠癌的疗效及安全性的差异,对临床用药进行指导。方法:对34例患者进行随机分为治疗组与对照组两组。治疗组患者运用化疗联合贝伐单抗或西妥昔单抗进行治疗。对照组只用化疗治疗。两组患者治疗周期都是三周一次,一共四个疗程。对两组患者的疗效的改善,患者的不良反应情况进行观察分析。结果:化疗联合靶向治疗的治疗组明显优于单纯化疗的对照组。恶心呕吐、腹泻、肝损害、骨髓抑制、神经系统不良反应等不良反应中,两组差异无统计学意义(P>0.05)。结论:在晚期结直肠癌患者中,化疗联合靶向治疗的疗效明显优于单纯化疗,不良反应发生率二者无明显差别。
OBJECTIVE: To compare the efficacy and safety of chemo-chemotherapy alone with chemotherapy plus bevacizumab or cetuximab in the treatment of advanced colorectal cancer, and to guide clinical medication. Methods: 34 patients were randomly divided into treatment group and control group. Patients in the treatment group were treated with chemotherapy combined with bevacizumab or cetuximab. The control group only chemotherapy treatment. Two groups of patients treatment cycle is once every three weeks, a total of four courses. The two groups of patients to improve the efficacy of adverse reactions in patients with observation and analysis. Results: Chemotherapy combined with targeted therapy in the treatment group was significantly better than the chemotherapy alone control group. Nausea and vomiting, diarrhea, liver damage, bone marrow suppression, adverse reactions of the nervous system and other adverse reactions, there was no significant difference between the two groups (P> 0.05). Conclusion: In patients with advanced colorectal cancer, chemotherapy combined with targeted therapy was significantly better than chemotherapy alone, the incidence of adverse reactions there was no significant difference between the two.